Company intelligence / Profile preview

DelMar Pharmaceuticals

San Diego, California, United Statesdelmarpharma.com ↗

Ownership: Private
Development stage: Phase 2

Overview

DelMar's lead drug VAL-083 showed promising clinical activity in Phase 2 trials for refractory glioblastoma multiforme. The company completed an End of Phase 2 meeting with the FDA in 2016 and planned to advance to Phase 3 trials.

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

VAL-083

Phase 2

Indications: Glioblastoma multiforme, Ovarian cancer

Partnerships

Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd.Duke University

Beyond the preview

Go deeper on DelMar Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DelMar Pharmaceuticals.

Explore the full profile